Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 325-329

  Ochiai, Takumi ^a   Nishimura, Kazuhiko ^a   Watanabe, Tomoo ^a   Kitajima, Masayuki ^a   Hashiguchi, Tadasuke ^a   Nakatani, Akinori ^a   Marusasa, Takashi ^a   Muraki, Akira ^a   Nagaoka, Isao ^b   Futagawa, Shunji ^a  

^a Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen gel droplet embedded drug sensitivity test; Colorectal cancer; FOLFIRI; FOLFOX; Individualized chemotherapy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; MONOTHERAPY;

EID: 77956197513     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000050     Document Type: Article

References (22)

1. Ochiai T, Nishimura K, Noguchi H, Kitajima M, Tsuruoka Y and Takahashi Y: Evaluation of 5-fluorouracil applicability by multi-point collagen gel droplet embedded drug sensitivity test. Oncol Rep 14: 201-205, 2005.
2. Ochiai T, Nishimura K, Noguchi H, et al: Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. Anticancer Drugs 18: 17-21, 2007.
3. Kobayashi H, Tanisaka K, Doi O, et al: An in vitro chemosensitivity test for soid human tumors using collagen gel droplet embedded cultures. Int J Oncol 11: 449-455, 1997.
4. Kobayashi H, Higashiyama M, Minamigawa K, et al: Examination of in vitro chemosensitivity test using collagen droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 92: 203-210, 2001.
5. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
6. Falcone A, Ricci S, Brunetti I, et al: Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
7. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
8. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
9. André T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343-1347, 1999.
10. Maindrault-Goebel F, Louvet C, André T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35: 1338-1342, 1999.
11. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
12. Matsuo A, Watanabe A, Takahashi T, et al: Asimple method for classification of cell death by use of thin layer collagen gel for the detection of apoptosis and/or necrosis after cancer chemotherapy. Jpn J Cancer Res 92: 813-819, 2001.
13. Kobayashi H: Development of a new in vitro chemosensitivity test using collagen gel droplet culture and image analysis for clinical usefulness. Recent Results Cancer Res 161: 48-61, 2003.
14. Ochiai T, Nishimura K, Noguchi H, et al: Prognotic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118: 3084-3088, 2006.
15. Minderman H, Conroy JM, O'Loughlin KL, et al: In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther 4: 885-900, 2005.
16. Lévi F, Metzger G, Massari C, et al: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 2000.
17. Guichard S, Hennebelle I, Bugat R, et al: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998.
18. Pavillard V, Formento P, Rostagno O, et al: Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56: 1315-1322, 1998.
19. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC and Bertino JR: Role of E2F-1 in chemosensitivity. Cancer Res 58: 4292-4296, 1998.
20. Fukushima M, Uchida J, Sakamoto K, Ohshima H and Taguchi T: Molecular mechanism of down-regulation by CPT-11 of thymidylate synthase highly expressing in gastrointestinal cancer xenografts during combined treatment with fluoropyrimidines. Eur J Cancer 1: S62, 2003.
21. Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250, 2004.
22. Fukushima M: S-1 review from preclinical pharmacology. Gastric Cancer 12: 3-9, 2009.